Generate Biomedicines stock ends week back above IPO price as volume jumps
Generate Biomedicines (NASDAQ:GENB) surged 13.7% since June 18 to close Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as investors weigh its $516.6M cash pile, ongoing clinical trial risks, and lack of product revenue, while sector momentum lifts biotech stocks.